Third Arc Bio: $52 Million Series A Extension Raised To Expand Oncology And Immunology Portfolio
By Amit Chowdhry ● Feb 4, 2026
Third Arc Bio announced it has closed a $52 million Series A extension financing, adding to a previously announced $165 million Series A as the company looks to broaden and accelerate its oncology and immunology and inflammation pipeline. The financing was led by new investor Andreessen Horowitz (a16z) alongside founding investor Omega Funds. The round also included participation from Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group. As part of the transaction, a16z General Partner Jorge Conde is joining Third Arc Bio’s board.